Skip to main content

Dyadic International, Inc. (DYAI)

NASDAQ: DYAI · IEX Real-Time Price · USD
5.67 0.05 (0.89%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap159.21M
Revenue (ttm)2.16M
Net Income (ttm)-11.60M
Shares Out28.08M
EPS (ttm)-0.42
PE Ration/a
Forward PE76.92
Dividendn/a
Ex-Dividend Daten/a
Volume183,515
Open5.65
Previous Close5.62
Day's Range5.54 - 5.75
52-Week Range3.15 - 8.78
Beta0.06
AnalystsStrong Buy
Price Target8.00 (+41.1%)
Est. Earnings DateNov 11, 2021

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins....

IndustryBiotechnology
IPO DateNov 5, 2004
Employees6
Stock ExchangeNASDAQ
Ticker SymbolDYAI
Full Company Profile

Financial Performance

In 2020, DYAI's revenue was $1.60 million, a decrease of -4.71% compared to the previous year's $1.68 million. Losses were -$9.33 million, 12.2% more than in 2019.

Financial Statements

Analyst Forecast

According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is 8.00.

Price Target
$8.00
(41.09% upside)
Analyst Consensus: Strong Buy

News

Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

JUPITER, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, a...

1 week ago - GlobeNewsWire

Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein t...

Other symbols:SRNE
1 month ago - Accesswire

Dyadic Stock Jumps On Development Pact With Sorrento For Diagnostics & Therapies For Coronaviruses

Dyadic International Inc (NASDAQ: DYAI) and Sorrento Therapeutics Inc (NASDAQ: SRNE) have announced a binding term sheet for a License Agreement to develop and commercialize vaccines, therapeutics, and ...

Other symbols:SRNE
1 month ago - Benzinga

Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic's Lead COVID-19 Vaccine Candidate “DYAI-100” and C1...

JUPITER, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, a...

1 month ago - GlobeNewsWire

Dyadic to Report Second Quarter 2021 Financial Results

JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying...

1 month ago - Accesswire

Best Penny Stocks to Buy Now? 4 to Watch During Earnings Season

With earnings season in full swing, which penny stocks are investors watching right now? The post Best Penny Stocks to Buy Now?

Other symbols:NBYSINTXELA
1 month ago - PennyStocks

Dyadic Stock Shoots Higher On Technology Transfer, Licensing Pact For COVID-19 Vaccine In African Continent

Dyadic International Inc (NASDAQ: DYAI) stock is trading higher during the morning session on high volume after signing a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Cons...

1 month ago - Benzinga

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa's Rubic Consortium Aiming to Develop a...

Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries

1 month ago - GlobeNewsWire

Dyadic's C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Jou...

JUPITER, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on deploying its propri...

2 months ago - GlobeNewsWire

The Vaccine Investment Hypothesis, and What's Next (AZN, JNJ, DYAI, BNTX)

The party is apparently “On” as far as the developed world's sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world's population have...

Other symbols:AZNBNTXJNJ
3 months ago - OTC PR Wire

Dyadic' Stock Jumps On COVID-19 Vaccine Development Pact In India

Dyadic International Inc (NASDAQ: DYAI) has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate. The company says that the vaccine can potentially provide...

3 months ago - Benzinga

Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA)

The process of lining up the next wave of vaccines – Vax 2.0 – is likely already underway behind closed doors at major science institutes, throughout top research think-tanks, and at the home bases of t...

Other symbols:MRNANVAXPFE
3 months ago - OTC PR Wire

Dyadic to Present at Upcoming Events

JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its pr...

3 months ago - Accesswire

Could Dyadic International (DYAI) be a Dark Horse Vaccine MVP

Dyadic International Inc (NASDAQ: DYAI) continues to take strong steps as a dark horse candidate to reshape the global vaccine landscape. The company posted results and an in-depth update late last week...

4 months ago - OTC PR Wire

Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

Advancing Dyadic 's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in humans and to accelerate ad...

4 months ago - Accesswire

DYAI's C1 Technology May be Key in the Race to Vaccine-Induced Herd Immunity

Dyadic International Inc (NASDAQ: DYAI) is in an interesting position, being one of the very few names in the anti-Covid space that offer a new path that isn't simply a reproduction or tie-in to the big...

4 months ago - OTC PR Wire

A New Technology that Could Reshape the Vaccine Playing Field (NASDAQ: DYAI) (NASDAQ: AZN) (NASDAQ: MRNA) (NASDAQ: NV...

The global distribution of Covid-19 vaccines has been dramatically short of hopes and expectations, but right in line with the warnings from skeptics who know the production constraints from traditional...

4 months ago - OTC PR Wire

Dyadic to Report First Quarter 2021 Financial Results

JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applyin...

4 months ago - Accesswire

Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYAI)

India is burning in Covid flames. Brazil is in basically the same shape.

4 months ago - OTC PR Wire

Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYIA)

India is burning in Covid flames. Brazil is in basically the same shape.

4 months ago - OTC PR Wire

Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in ...

Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time

5 months ago - GlobeNewsWire

Is Dyadic International Inc. (NASDAQ: DYAI) the Key to the Next Wave of Vaccinations? (NASDAQ: AZN) (NASDAQ: MRNA) (N...

Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations tha...

5 months ago - OTC PR Wire

How Dyadic International Inc (NASDAQ: DYAI) Fits into the Vaccine 2.0 Gold Rush (NASDAQ: BNTX) (NYSE: JNJ) (NASDAQ: M...

Death, Taxes, and Covid shots. The future stretching out in front of us has maybe only these three certainties.

5 months ago - OTC PR Wire

Dyadic Reports 2020 Year End Results and Recent Company Progress

Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and ...

5 months ago - Accesswire

Is Dyadic International Inc (NASDAQ: DYAI) the Key to Scaling Up Global Access to a Viable Covid-19 Vaccine? (NASDAQ:...

While the pandemic feels “almost over” on many levels, experts believe the fundamental driver – a rapidly mutating coronavirus pathogen with uniquely formidable qualities – is likely, and unfortunately,...

5 months ago - OTC PR Wire